Marengo Therapeutics to Present Clinical Data on Invikafusp Activity
Overview of the Presentation:
Marengo Therapeutics, Inc. a clinical-stage biotech company, is poised to share pivotal clinical data regarding its leading candidate, invikafusp alfa (STAR0602). This data stems from the STARt-001 trial, highlighting the agent's single-agent anti-tumor activity, particularly focusing on patients with PD1-resistant tumors. During the upcoming American Association of Cancer Research (AACR) Annual Meeting, set for April 2025, these crucial findings will be unveiled during a clinical plenary oral presentation.
Details of the Clinical Study Presentation
The clinical presentation will occur during the conference and will delve into the essential outcomes from the STARt-001 trial. This trial is instrumental as it marks a phase 1/2 evaluation of invikafusp alfa in patients who have exhibited resistance to existing PD1 therapies.
Presentation Information
- Title: Updated Clinical Results, Recommended Phase 2 Dose (RP2D) Determination, and Translational Study Results for STARt-001
- Conference: AACR Annual Meeting 2025
- Abstract Number: CT205
- Session Title: Clinical Trials Plenary: Biologics and T-cell Engagers
- Date and Time: Tuesday, April 29, 2025, 10:15 AM - 12:15 PM
- Presenter: Dr. Ryan J. Sullivan, Massachusetts General Hospital
About Marengo Therapeutics
Marengo Therapeutics is at the forefront of developing breakthrough immunotherapies. The company specializes in innovative T-cell activating therapies aimed at treating cancer and autoimmune disorders. By employing their proprietary technologies, the firm aims to strategically engage T cells to combat malignancies effectively.
The STAR™ Platform Explained
The STAR™ platform developed by Marengo Therapeutics represents a significant technological advancement in antibody-based therapies. This multi-specific antibody-fusion platform is derived from a library of antibodies that target specific regions of the T-cell receptor. By fusing these antibodies with co-stimulatory signals, the platform seeks to foster stronger and more durable immune responses against tumors.
About Invikafusp alfa (STAR0602)
Invikafusp alfa, as the flagship candidate from the STAR™ platform, is engineered to selectively activate vital T cell subsets present in various cancers. This unique mechanism of action supports the proliferation of potent, memory T cells, leading to enhanced anti-tumor activity and potentially long-lasting resistances against tumor recurrence.
Understanding the STARt-001 Clinical Study
The STARt-001 trial is a comprehensive phase 1/2 study aimed at assessing the safety and preliminary efficacy of invikafusp alfa in patients who have advanced antigen-rich solid tumors. Notably, this includes those who show resistance to PD-1 therapies and other less common tumors. It comprises two sequential parts: a dose escalation phase followed by a dose expansion utilized to further evaluate the drug’s effectiveness.
Frequently Asked Questions
What is the focus of the STARt-001 trial?
The STARt-001 trial is focused on evaluating the safety and efficacy of invikafusp alfa in patients with advanced solid tumors that are resistant to PD1 inhibitors.
When will Marengo present the updated data?
The updated clinical data will be presented during the AACR Annual Meeting on April 29, 2025.
Who will present the findings?
The findings will be presented by Dr. Ryan J. Sullivan from Massachusetts General Hospital.
What is invikafusp alfa?
Invikafusp alfa is a novel therapy designed to activate specific T cell populations to enhance anti-tumor immune responses.
How can patients participate in the study?
Patients can inquire about participation by contacting cancer research networks or visiting relevant clinical trial websites.
